Cardiovascular diseases represent a significant cause of morbidity and mortality in diabetes. Of the many animal models used in the study of non-insulin-dependent (type 2) diabetes, the JCR:LA-cp rat is unique in that it develops insulin resistance in the presence of obesity and manifests both peripheral and coronary vasculopathies. In this animal model, arterial vascular smooth muscle cells (VSMCs) from homozygous obese (cp/cp) rats, but not from age-matched healthy (؉/؉ or ؉/cp, collectively defined ؉/?) littermates, display an "activated" phenotype in vitro and in vivo and have an elevated level of cAMP phosphodiesterase (PDE) activity. In this report, we confirm that cp/cp rat aortic VSMCs have an elevated level of PDE3 activity and show that only particulate PDE3 (PDE3B) activity is elevated. In marked contrast to results obtained in ؉/? VSMCs, simultaneous activation of adenylyl cyclase and inhibition of PDE3 activity in cp/cp VSMCs synergistically increased cAMP. Although PDE3 inhibition did not potentiate the antimigratory effects of forskolin on ؉/? VSMCs, PDE3 inhibition did markedly potentiate the forskolin-induced inhibition of migration of cp/cpderived VSMCs. Although PDE3 activity was elevated in cp/cp rat aortic VSMCs, levels of expression of cytosolic PDE3 (PDE3A) and PDE3B in ؉/? and cp/cp VSMCs, as well as activation of these enzymes following activation of the cAMP-protein kinase A signaling cascade, were not different. Our data are consistent with an increased role for PDE3 in regulating cAMP-dependent signaling in cp/cp VSMCs and identify PDE3 as a cellular activity potentially responsible for the phenotype of cp/cp VSMCs.
A therosclerosis and other cardiovascular diseases are much more prevalent in people with diabetes than in the population at large and represent a significant cause of morbidity and early mortality in diabetes (1) (2) (3) (4) (5) . In this context, epidemiological evidence consistent with an increased risk of atherosclerosis in diabetes is mounting, with a possible role for 1) insulin resistance and its associated hyperinsulinemia, 2) poor glycemic control leading to elevated levels of advanced glycosylated end products, or 3) elevated circulating leptin levels associated with increased adipose mass (1) (2) (3) (4) (5) . Atherosclerotic lesions occur in the context of endothelial cell dysfunction and involve activation, migration, and proliferation of vascular smooth muscle cells (VSMCs). A link between an "activated" phenotype of VSMC in diabetes and atherosclerosis has been documented in animal models and humans (6) .
Endothelium-derived relaxing factors, such as nitric oxide or prostacyclin, relax blood vessels and inhibit the proliferation and migration of VSMCs by increasing the synthesis of the cyclic nucleotides cAMP or cGMP (7) (8) (9) (10) . A large family of enzymes named cyclic nucleotide phosphodiesterases (PDEs) inactivate cAMP and cGMP through their hydrolysis (11) (12) (13) (14) . VSMC cAMP hydrolysis is catalyzed by members of the phosphodiesterase 3 (PDE3) and PDE4 families (12) , whereas VSMC cGMP is inactivated by PDE1 or PDE5 enzymes (15) .
Hydrolysis of cAMP by PDE3 is potently inhibited by cGMP, as well as by a large number of pharmacological agents capable of stimulating myocardial contractility, inhibiting platelet aggregation, and relaxing vascular and airway smooth muscle (e.g., cilostamide, enoximone, lixazinone) (11,13,16 -19) . Two different genes encoding PDE3 activity have been identified, PDE3A and PDE3B, and each is expressed in rat and human VSMCs (20, 21) . Forskolin, ␤-adrenergic agonists, or glucagon increase cAMP and activate PDE3 through a cAMP-dependent protein kinase A (PKA)-mediated phosphorylation. Similarly, insulin, IGF-1, or leptin activates PDE3 by a protein kinase B (PKB)-mediated, phosphatidylinositol 3-kinase (PI3K)-dependent phosphorylation reaction. Indeed, activation of particulate PDE3 (PDE3B) by insulin in adipocytes, leptin in hepatocytes, or IGF-1 in pancreatic ␤-cells has been shown to be essential for the metabolic effects of these hormones in these tissues (22) (23) (24) . Four PDE4 genes have been identified, PDE4A, PDE4B, PDE4C, and PDE4D (25) . Perhaps owing to the weak vasorelaxation caused by PDE4 inhibition (12) , expression of these enzymes in VSMCs has not been extensively studied. Recently, we demonstrated that two PDE4D variants (PDE4D3 and PDE4D5) are expressed in both rat and human VSMCs (26, 27) . As with PDE3, PKA-dependent phosphorylation of some PDE4s, including PDE4D3, stimulates these enzymes (28, 29) . Activation of the mitogen-activated protein kinase (MAPK) cascade can activate, or inhibit, PDE4 perhaps in a cell type-dependent manner (26, 30) .
Of the many animal models used in the study of noninsulin-dependent (type 2) diabetes, the JCR:LA-cp rat is unique in that it develops insulin resistance in the presence of obesity and manifests both peripheral and coronary vasculopathies (6, 31) . Although the homozygous (ϩ/ϩ) and heterozygous (ϩ/cp) animals (collectively defined ϩ/?) are metabolically normal, homozygotes for the autosomal recessive corpulent gene (cp/cp) are insulin resistant, hyperinsulinemic, obese, glucose intolerant, and hyperlipidemic and show signs of pancreatic ␤-cell hyperplasia (31) . In previous reports, cp/cp VSMCs have been shown to display an activated phenotype, compared with ϩ/? VSMCs, both in vivo and after culture (6, 32, 33) . Regrettably, little is known concerning the molecular basis of this activated phenotype. In one previous report, cp/cp rat aortae were shown to express increased PDE3 and PDE4 activities compared with aortae from age-matched ϩ/? littermates (34). In the work described in this report, we have confirmed that cp/cp rat aortic VSMCs have elevated PDE3 activity and that this activity plays an important role in cAMP catabolism in cp/cp VSMCs. Our data are discussed in the context of the hypothesis that aberrant regulation of PDE3 activity in cp/cp VSMCs may alter the capacity of these cells to regulate cAMP-mediated effects.
RESEARCH DESIGN AND METHODS
Aortic tissues and cultured aortic cells. Care provided for the rats and the treatments used in experiments conformed to the guidelines of the Canadian Council on Animal Care and were subject to prior institutional approval. JCR:LA-cp rats were bred at the University of Alberta as described previously (35) . Rat aortic tissues were collected from anesthetized animals (4% halothane). JCR:LA-cp rat aortic VSMCs were grown from explanted segments of aorta isolated from 3-week-old or 6-month-old rats and subcultured as described previously (33, 36) . Cells between passages 4 and 10 were used in these studies; no passage-dependent differences were observed. Measurement of cAMP PDE activity. Total cAMP PDE, PDE3, and PDE4 activities in lysates of aortic tissues or of cultured VSMCs were measured as described previously (35) , with isobutyl-methylxanthine (500 mol/l), cilostamide (1 mol/l), or Ro,201724 (10 mol/l) used to determine total, PDE3, and PDE4 cAMP PDE activities, respectively. Concentrations of cilostamide and Ro,201724 used in these experiments were chosen from concentrationresponse curve analyses with each VSMC cell type. Because combinations of these two agents with concentrations of cilostamide Ͼ1 mol/l and Ro,201724 Ͼ10 mol/l were subadditive, and hence nonselective, those maximally effective concentrations were used. When PDE3 and PDE4 activities were measured in isolated cytosolic and particulate fractions of aortic tissue or of VSMCs, subcellular fractions were isolated by ultracentrifugation as described previously (20) . Immunoblot analysis. PDE3 expression was verified and quantitated by immunoblot analysis using procedures described previously (20, 21) . Three separate antisera were used: a rabbit polyclonal antibody generated against the carboxy-terminal region of a murine PDE3B as antigen (provided by Dr. J.A. Beavo, University of Washington, Seattle, WA) and two polyclonal antisera raised to amino-and carboxy-terminal regions of human PDE3 (Santa-Cruz Biotech, Santa Cruz, CA). Determination of VSMC cAMP levels. Drug-induced changes in VSMC cAMP were measured using a prelabeling method described previously (37) . Briefly, VSMC ATP was metabolically labeled by incubation of cells with 2 mol/l [ 3 H]hypoxanthine (10 Ci/ml for 16 h). Prelabeled VSMCs were incubated with pharmacological agents, and incubations were terminated by addition of trichloroacetic acid (5% vol/vol final concentration). [ 3 H]cAMP was isolated and purified by sequential chromatography on alumina/Dowex and quantitated by liquid scintillation (37) . Migration assays. Two separate migration assays were used in these studies. The modified Boyden chamber assay was conducted as previously described by us (38) . The radial invasion of matrix by aggregated cells (RIMAC) assay was carried out as described previously (39) , except that VSMCs were used rather than bovine aortic endothelial cells.
RESULTS

PDE3
and PDE4 activities in JCR:LA-cp rat aortae. Aortic cAMP PDE activity of the JCR:LA-cp rat strain was predominantly made up of PDE3 and PDE4 activities (Table 1) . Consistent with a previous report (34) , PDE3 activity of aortae derived from 6-month-old cp/cp rats was elevated significantly (18 Ϯ 3%, n ϭ 9) compared with that of age-matched controls (ϩ/?). In contrast, no differences in PDE4 activity in aortic tissues isolated from cp/cp and ϩ/? aortae were noted ( Table 1) . Analysis of cytosolic and particulate cAMP PDE activity identified an increase in particulate PDE3 activity in cp/cp rat aortic tissue compared with ϩ/? aortae. There were no differences in cytosolic PDE3 activity between ϩ/? and cp/cp aortae (Table 1) .
PDE3 and PDE4 activities and expression in JCR:
LA-cp rat aortic VSMCs. To more fully assess the potential significance of differences in PDE3 activity in cp/cp aortae, we determined the PDE3 and PDE4 activities We have reported previously that PDE3A and PDE3B were both expressed in rat and human aortic VSMCs, and that these two enzymes were selectively expressed in cytosolic (PDE3A) and particulate (PDE3B) fractions of rat tissues, respectively. Because particulate PDE3 activity was selectively elevated in cp/cp aortae and cultured aortic VSMCs (Tables 1 and 2 ), we hypothesized that levels of PDE3B would be elevated in cp/cp tissues relative to ϩ/? tissues. Immunoblot analysis using several PDE3A and PDE3B antisera revealed the expression of a 105-kDa cytosolic PDE3A and a 135-kDa particulate PDE3B in both ϩ/? and cp/cp VSMCs. In contrast to our prediction, however, of the four separate VSMC samples of each (ϩ/? and cp/cp) that were immunoblotted using five separate antisera for PDE3A or PDE3B, there were no significant differences detected in the levels of PDE3A or PDE3B expressed (representative immunoblot, Fig. 1 ). Consistent with the activity data, levels of PDE4D expression were similar between ϩ/? and cp/cp VSMCs (not shown). Effects of forskolin, phorbol myristate acetate (PMA), or IGF-1 on ؉/? or cp/cp VSMC PDE3 activity. As described above, activation of either the cAMP-PKA or the PI3K-PKB signaling cascades increases PDE3 activity in some cell types. To assess the possibility that differences in the regulation of PDE3 activity were involved in the altered PDE3 activity in cp/cp VSMCs, we measured PDE3 activity in ϩ/? or cp/cp VSMCs after incubation with agents that would activate PKA (50 mol/l forskolin for 20 min) (26 -27) or PI3K-PKB (100 nmol/l PMA for 20 min or 100 ng/ml IGF-1 for 5 min) (22) (23) (24) . Our data were not consistent with the idea that differences in PKA or PI3K-PKB activation of PDE3 played a major role in the observed differences in particulate PDE3 activity between ϩ/? and cp/cp VSMCs. Thus, incubation of VSMCs with forskolin increased particulate PDE3 activity by 20 Ϯ 2% and 23 Ϯ 3% in ϩ/? and cp/cp VSMCs, respectively. The magnitude of this effect was similar to that previously reported by us for VSMCs cultured from Wistar rat aortae (27, 36) . Similarly, whereas incubation of ϩ/? or cp/cp VSMCs with PMA or IGF-1 stimulated PDE4D3 activity by a MAPK-dependent mechanism (which we have reported previously [26 -27] ) and led to the accumulation of phosphorylated PKB (as determined using a phospho-PKB selective antisera [not shown]), neither of these agents altered cytosolic or particulate PDE3 activity in either VSMC population. Selective inhibition of PDE3 activity in cp/cp VSMCs and adenylyl cyclase activation-mediated increases in cAMP. In previous work, we reported that increases in VSMC cAMP resulting from activation of adenylyl cyclase could be potentiated by simultaneous inhibition of VSMC PDE activity (26, 27, 36) . Moreover, we showed that the level of potentiation achieved correlated to the cellular level of cAMP PDE activity. Using the same approach, we undertook to determine if the slight elevation of PDE3 activity detected in cp/cp VSMCs could alter the impact of PDE3 inhibition on cAMP responses in these cells. Our data identify a marked increase in the contribution of PDE3, relative to PDE4, to cAMP hydrolysis in cp/cp VSMCs compared with ϩ/? VSMCs ( Fig. 2A-D) .
Whereas cilostamide had no effect on forskolin-induced 
Cilostamide (1 mol/l), Ro,201724 (10 mol/l), and IBMX (500 mol/l) were used to determine PDE3, PDE4, and total cAMP PDE activities, respectively. Data are means Ϯ SE from three independent determinations. Similar results were obtained in seven independent experiments conducted in triplicate. *Significant difference compared with particulate PDE3 activity in cultured ϩ/? aortic VSMCs; P Ͻ 0.05.
PDE3 AND HYPERMOTILE cp/cp VSMCs
increases in cAMP in ϩ/? VSMCs, this PDE3 inhibitor markedly potentiated the forskolin-induced increases in cAMP in cp/cp VSMCs ( Fig. 2A and B) . The inability of cilostamide to increase cAMP in ϩ/? VSMC cAMP was consistent with previous work from our laboratory using VSMCs derived from other rat strains (36, 38) . Similar results were obtained when VSMC adenylyl cyclase was stimulated using isoproterenol or adenosine. Thus, whereas cilostamide did not increase the amount of cAMP that accumulated in response to isoproterenol or adenosine in ϩ/? VSMCs, this agent markedly increased their effects in cp/cp VSMCs ( Fig. 2C and D) . Because 6-month-old rats would have established insulin resistance, similar experiments were carried out using VSMCs derived from 3-weekold rats, an age at which both ϩ/? and cp/cp rats have normal insulin sensitivity and are essentially normoinsulinemic. In all respects, data obtained with VSMCs derived from the 3-week-old animals mirrored those obtained with the VSMCs derived from the older animals (Table 3) .
Hypermotile phenotype of VSMCs derived from cp/cp rats. In a previous report, cp/cp aortic VSMCs were shown to exhibit a hyperproliferative phenotype relative to age-matched ϩ/?-derived aortic VSMCs (33) . Because VSMC migration is critical to development of diabetes- [38] ) and three-dimensional (RIMAC [39] ) migration assays, cp/cp-derived aortic VSMCs were shown to be hypermotile relative to age-matched ϩ/? aorta-derived VSMCs. Indeed, marked differences in basal and stimulated migration were observed between these cells in each assay (Table 4 ; Fig. 3 ).
Effects of cilostamide on migration of cp/cp and ؉/?
VSMCs. Because we had previously shown that forskolin inhibited platelet-derived growth factor (PDGF)-induced migration and that PDE inhibition could markedly potentiate this effect (38), we next determined if a functional link existed between the increased role of PDE3 in cAMP signaling in cp/cp VSMCs and the hypermotile phenotype of these cells. Consistent with our previous work, cilostamide did not inhibit migration of ϩ/? VSMCs, nor did it increase the inhibition of migration caused by forskolin. In contrast, cilostamide caused a slight inhibition of PDGFinduced migration in cp/cp VSMCs and markedly potentiated the inhibitory effect of forskolin in these VSMCs (Table 5 ). In fact, the inhibition caused by simultaneous addition of forskolin and cilostamide in cp/cp VSMCs was larger than that caused by the combined actions of forskolin and Ro,201724 in these cells. This effect of cilostamide correlated positively with the effect of this PDE3 inhibitor on forskolin-, isoproterenol-, or adenosineinduced increases in cAMP in cp/cp VSMCs (Fig. 2) , which supports the concept that even relatively minor differences in PDE3 activity between different VSMCs can have marked effects on cAMP-dependent VSMC function such as migration.
DISCUSSION
Because an activated VSMC phenotype in obese cp/cp JCR:LA-cp rats predisposes these animals to the development of cardiovascular disease, our aim in this study was to determine if differences in arterial VSMC cAMP PDE activity between lean and obese JCR:LA-cp rats were involved in this activated phenotype. Overall, our findings are consistent with an increased role for PDE3 in the inactivation of cAMP in obese cp/cp rat arterial VSMCs and define PDE3 as a potential cellular activity responsible for this activated phenotype. In this study, we confirmed previous work of others (34) indicating that at 6 months, the cp/cp rat aorta has higher PDE3 activity than age-matched lean ϩ/? rat aorta. Although our findings were in general agreement with those reported previously, some differences were observed. Whereas Nagaoka et al. (34) described a twofold higher PDE3 activity in cp/cp aorta than in ϩ/? aorta, a much more modest difference (ϳ18%) was observed in our studies. Similarly, whereas Nagaoka et al., reported increased PDE4 activity in aorta of cp/cp animals, no such difference was observed in our experiments. Although the basis for these differences has not been fully elucidated, we suggest that the differences in total cAMP PDE activity determined for aorta isolated from 3-week-old and 6-month-old animals in the earlier report may have been a contributing factor. In this context, no age dependence of cAMP-PDE activity was seen in our experiments. Whereas the increase in cp/cp aortic PDE3 activity reported by Nagaoka et al. (34) correlated positively with an increased amount of PDE3A mRNA, no differences in PDE3A or PDE3B expression were observed in our experiments. Although PDE3A and PDE3B mRNA levels were not measured in our studies, based on our finding that similar amounts of these proteins were expressed in ϩ/? and cp/cp aorta using five distinct PDE3 antibodies, we conclude that PDE3A and PDE3B expression is not different between these ϩ/? and cp/cp tissues. Interestingly, we show that the difference in PDE3 activity in the aorta was maintained when aortic VSMCs were cultured from these animals. This fact lends credence to the hypothesis that the difference observed in the aorta is related to differences in aortic VSMCs, and that the differences in PDE3 activity detected between ϩ/? and cp/cp VSMCs were intrinsic to these cells (40) and not due to the influence of blood-borne factors that could potentially influence PDE3 activity. The molecular basis for the increase in particulate PDE3 activity in cp/cp VSMCs, in the absence of elevated expression of PDE3B in these cells, has not yet been fully elucidated, although we have tested several potential mechanisms. Based on our studies, it is unlikely that differences in PKA or PI3K-PKB signaling between these cells could account for the increase in particulate PDE3 detected in cp/cp VSMCs. Indeed, incubation of VSMCs with agents shown to activate PKA or PI3K-PKB, in both ϩ/? and cp/cp VSMCs, had the expected impact on VSMC PDE4D activity and identical effects on PDE3 activity. Further studies, perhaps using cell types expressing significantly larger levels of PDE3, will be required to determine the molecular basis for the differences observed in this study. For example, if the increased particulate PDE3 activity seen in cp/cp VSMCs was due to aberrant targeting of this enzyme between the endoplasmic reticulum (41) or plasma membrane (42, 43) , levels of PDE3B in the cells used in this study would likely prohibit analysis of this event.
A novel, intriguing, and potentially important finding of our work is that the modest increase in particulate PDE3 activity detected in cp/cp VSMCs was associated with marked changes in the role of this enzyme in these cells. Whereas selective pharmacological inhibition of PDE3 had no effect on forskolin-, isoproterenol-, or adenosineinduced increases in cAMP in ϩ/? VSMCs (results consistent with data reported previously using Wistar aortic VSMCs [36] ), similar incubation of cp/cp VSMCs caused markedly different responses. Indeed, selective pharmacological inhibition of PDE3 in cp/cp VSMCs resulted in a large potentiation of the increase in cAMP caused by each of these agents. These results are all the more intriguing if one considers that PDE3 activity in VSMCs represents Ͻ30% of the total cAMP PDE activity in each of these populations of VSMCs. In addition, we found that the increase in PDE3 activity was limited to the subcellular fraction expressing only PDE3B, and not the more dominant PDE3A, expanding on earlier findings of Chini et al. (44) showing that individual cellular functions could be regulated in cAMP PDE-dependent fashions. Indeed, our work expands this finding to include differential effects of isozymes of the same cAMP PDE family.
Previous work has been reported indicating that cp/cp VSMCs exhibit an activated behavior in vivo characterized by an irregular shape and a propensity to migrate from the medial layer and invade the intimal layer (6, 32) . In addition, cultured cp/cp VSMCs display a hyperproliferative phenotype in response to several mitogens (33) . We report here that cp/cp VSMCs are hypermotile in response to two chemotactic agents, IGF-1 and PDGF. The exaggerated response of cp/cp VSMCs to these factors is consistent with the earlier reports and adds motility and invasion of extracellular matrix to the list of exaggerated responses of these phenotypically activated cells. Although the molecular basis for the hypermotility of the cp/cp VSMCs has not been determined, from our studies a possible role for PDE3 is evident. Because pharmacological inhibition of PDE3 activity in cp/cp VSMCs markedly increases the antimigratory and invasion effects of forskolin in cp/cp VSMCs, but not ϩ/? VSMCs, our data are consistent with a role for PDE3 in the hypermotile and invasive potential of these cells. Although the effectiveness of the PDE3 inhibitor was perhaps unexpected given the modest fraction of the total cAMP PDE activity that this agent inhibited, its impact was entirely consistent with its impact on VSMC cAMP levels.
In conclusion, our study provides a comprehensive analysis of cAMP PDE activity expressed in aortic VSMCs from lean and obese JCR:LA cp rats and describes a marked difference in the contribution of PDE3 to cAMP hydrolysis in aortic VSMCs isolated from the obese and lean animals. Moreover, we show that the cp/cp VSMCs display an exaggerated motility and invasiveness compared with ϩ/? VSMCs that is sensitive to PDE3 inhibition. Because the JCR:LA-cp strain develops insulin resistance and hyperinsulinemia, is both glucose intolerant and hyperlipidemic, and has been an extensively studied model of type 2 diabetes that develops cardiovascular disease, we believe our findings should stimulate further interest in PDE3 as a therapeutic target in continuing efforts to reduce diabetes-associated cardiovascular disease.
